StocksMedium•12 October 2026•
1 min read
Bausch + Lomb Names Thomas Appio Interim CEO, Raises 2026 Financial Guidance
Key Facts
1Thomas J. Appio has been appointed interim CEO of Bausch + Lomb while maintaining his role as CEO of Bausch Health.
2Bausch + Lomb expects to raise its full-year 2026 financial guidance.
Bausch + Lomb has appointed Thomas J. Appio as interim CEO while he maintains his current role as CEO of Bausch Health. Business Wire reported that the company also expects to raise its full-year 2026 financial guidance, a move aimed at consolidating management during a period of strong performance.
BLCO closed at $17.30 on October 9, 2026, while the related BHC shares closed at $6.04 on the same date. This leadership transition coincides with positive signals regarding the company's financial trajectory, with BLCO reaching a session high of $17.47 on October 9.